{"entity":{"id":"shanghai-chest-hospital","kind":"institution","name":"Shanghai Chest Hospital","aka":["Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine","上海市胸科医院"],"tldr":"Shanghai Chest Hospital, China's first specialist chest hospital (1957), performs one of the world's largest volumes of lung and oesophageal operations and houses the Shanghai Lung Cancer Center; its investigators led the Chinese registration trials of EGFR, ALK and ROS1 inhibitors.","summary":"Founded in 1957 as China's first specialist chest hospital, Shanghai Chest performs one of the largest volumes of lung and oesophageal operations in the world each year and houses the Shanghai Lung Cancer Center directed by Shun Lu. Its investigators have led Chinese registration trials of EGFR, ALK and ROS1 inhibitors and PD-1 combinations, and contributed to the global osimertinib, lorlatinib and amivantamab programmes. Thoracic surgery, oesophageal cancer, thymic tumours and interventional bronchoscopy are core strengths, with robotic and uniportal video-assisted surgery widely used. The hospital is a national clinical research centre for respiratory disease.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Shanghai_Chest_Hospital","links":[{"label":"Shanghai Chest Hospital","url":"https://www.shxkyy.com"},{"label":"Shanghai Jiao Tong University School of Medicine","url":"https://www.shsmu.edu.cn"}],"tags":[],"related":[],"cancers":["nsclc","sclc","esophageal","mesothelioma"],"sections":["targeted-therapy","surgery"],"technologies":["kinase-inhibitors","robotic-surgery"],"targets":["egfr","alk","ret","met"],"drugs":["osimertinib","lorlatinib","amivantamab","ivonescimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["lu-shun"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Shanghai","country":"CN","lat":31.218,"lng":121.437,"institutionType":"hospital","website":"https://www.shxkyy.com","university":"Shanghai Jiao Tong University","programs":["Lung cancer targeted therapy trials","Thoracic surgery","Oesophageal cancer","Thymic tumours"]},"route":"/institutions/shanghai-chest-hospital/","neighbours":{"cancer":[{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"section":[{"id":"surgery","kind":"section","name":"Surgery & Interventional","route":"/fronts/surgery/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"robotic-surgery","kind":"technology","name":"Robotic & minimally invasive surgery","route":"/technologies/robotic-surgery/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/"},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"met","kind":"target","name":"MET","route":"/targets/met/"},{"id":"ret","kind":"target","name":"RET","route":"/targets/ret/"}],"drug":[{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/"},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"},{"id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"}],"person":[{"id":"lu-shun","kind":"person","name":"Shun Lu","route":"/people/lu-shun/"}],"trial":[{"id":"alter-0303","kind":"trial","name":"ALTER 0303","route":"/trials/alter-0303/"},{"id":"furlong","kind":"trial","name":"FURLONG","route":"/trials/furlong/"}]}}